Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Glycolysis Regulates Human Embryonic Stem Cell Self-Renewal under Hypoxia through HIF-2α and the Glycolytic Sensors CTBPs.

Arthur SA, Blaydes JP, Houghton FD.

Stem Cell Reports. 2019 Apr 9;12(4):728-742. doi: 10.1016/j.stemcr.2019.02.005. Epub 2019 Mar 14.

2.

Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization.

Banerjee A, Birts CN, Darley M, Parker R, Mirnezami AH, West J, Cutress RI, Beers SA, Rose-Zerilli MJJ, Blaydes JP.

Carcinogenesis. 2019 Jul 20;40(7):871-882. doi: 10.1093/carcin/bgy174.

PMID:
30668646
3.

HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma.

Fleming JC, Woo J, Moutasim K, Mellone M, Frampton SJ, Mead A, Ahmed W, Wood O, Robinson H, Ward M, Woelk CH, Ottensmeier CH, King E, Kim D, Blaydes JP, Thomas GJ.

Br J Cancer. 2019 Feb;120(3):356-367. doi: 10.1038/s41416-018-0364-7. Epub 2019 Jan 17.

4.

The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells.

Banerjee A, Arvinrad P, Darley M, Laversin SA, Parker R, Rose-Zerilli MJJ, Townsend PA, Cutress RI, Beers SA, Houghton FD, Birts CN, Blaydes JP.

Oncotarget. 2018 May 1;9(33):23274-23288. doi: 10.18632/oncotarget.25299. eCollection 2018 May 1.

5.

Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.

Smith LD, Leme de Calais F, Raponi M, Mellone M, Buratti E, Blaydes JP, Baralle D.

Int J Cancer. 2017 Apr 1;140(7):1564-1570. doi: 10.1002/ijc.30574. Epub 2017 Jan 30.

6.

The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ.

Papadakis ES, Barker CR, Syed H, Reeves T, Schwaiger S, Stuppner H, Troppmair J, Blaydes JP, Cutress RI.

Oncogenesis. 2016 Apr 4;5:e215. doi: 10.1038/oncsis.2016.10.

7.

Synthesis and evaluation of a (3R,6S,9S)-2-oxo-1-azabicyclo[4.3.0]nonane scaffold as a mimic of Xaa-trans-Pro in poly-L-proline type II helix conformation.

Aillard B, Kilburn JD, Blaydes JP, Tizzard GJ, Findlow S, Werner JM, Bloodworth S.

Org Biomol Chem. 2015 Apr 21;13(15):4562-9. doi: 10.1039/c5ob00180c.

PMID:
25777583
8.

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma.

Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C, Primrose JN, Blaydes JP, Thomas GJ.

J Pathol. 2015 Feb;235(3):466-77. doi: 10.1002/path.4467.

9.

Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.

Polański R, Noon AP, Blaydes J, Phillips A, Rubbi CP, Parsons K, Vlatković N, Boyd MT.

Cancer Lett. 2014 Oct 28;353(2):211-9. doi: 10.1016/j.canlet.2014.07.024. Epub 2014 Jul 24.

PMID:
25067787
10.

Transcription of click-linked DNA in human cells.

Birts CN, Sanzone AP, El-Sagheer AH, Blaydes JP, Brown T, Tavassoli A.

Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2362-5. doi: 10.1002/anie.201308691. Epub 2014 Jan 22.

11.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

12.

A cyclic peptide inhibitor of C-terminal binding protein dimerization links metabolism with mitotic fidelity in breast cancer cells.

Birts CN, Nijjar SK, Mardle CA, Hoakwie F, Duriez PJ, Blaydes JP, Tavassoli A.

Chem Sci. 2013 Aug 1;4(8):3046-3057. doi: 10.1039/c3sc50481f.

13.

Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization.

Spurr IB, Birts CN, Cuda F, Benkovic SJ, Blaydes JP, Tavassoli A.

Chembiochem. 2012 Jul 23;13(11):1628-34. doi: 10.1002/cbic.201200279. Epub 2012 Jul 4.

14.

Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids.

Collins SL, Hervé R, Keevil CW, Blaydes JP, Webb JS.

PLoS One. 2011;6(12):e28123. doi: 10.1371/journal.pone.0028123. Epub 2011 Dec 1.

15.

Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4.

Warenius HM, Kilburn JD, Essex JW, Maurer RI, Blaydes JP, Agarwala U, Seabra LA.

Mol Cancer. 2011 Jun 13;10:72. doi: 10.1186/1476-4598-10-72.

16.

CtBPs promote mitotic fidelity through their activities in the cell nucleus.

Birts CN, Bergman LM, Blaydes JP.

Oncogene. 2011 Mar 17;30(11):1272-80. doi: 10.1038/onc.2010.507. Epub 2010 Nov 8.

PMID:
21057548
17.

Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.

Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, Cutress RI, Bateman AC, Blaydes JP.

Biol Cell. 2010 Jan;103(1):1-19. doi: 10.1042/BC20100067.

18.

A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture.

Underwood TJ, Derouet MF, White MJ, Noble F, Moutasim KA, Smith E, Drew PA, Thomas GJ, Primrose JN, Blaydes JP.

Biol Cell. 2010 Dec;102(12):635-44. doi: 10.1042/BC20100071.

PMID:
20843300
19.

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival.

Wheater MJ, Johnson PW, Blaydes JP.

Cancer Biol Ther. 2010 Oct 1;10(7):728-35. doi: 10.4161/cbt.10.7.12965. Epub 2010 Oct 1.

20.

HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.

Phillips A, Teunisse A, Lam S, Lodder K, Darley M, Emaduddin M, Wolf A, Richter J, de Lange J, Verlaan-de Vries M, Lenos K, Böhnke A, Bartel F, Blaydes JP, Jochemsen AG.

J Biol Chem. 2010 Sep 17;285(38):29111-27. doi: 10.1074/jbc.M110.129726. Epub 2010 Jul 20.

21.

CtBPs promote cell survival through the maintenance of mitotic fidelity.

Bergman LM, Birts CN, Darley M, Gabrielli B, Blaydes JP.

Mol Cell Biol. 2009 Aug;29(16):4539-51. doi: 10.1128/MCB.00439-09. Epub 2009 Jun 8.

22.

Dissection of the functional interaction between p53 and the embryonic proto-oncoprotein PAX3.

Underwood TJ, Amin J, Lillycrop KA, Blaydes JP.

FEBS Lett. 2007 Dec 22;581(30):5831-5. Epub 2007 Nov 29.

23.

MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.

Phillips A, Blaydes JP.

Oncogene. 2008 Mar 6;27(11):1645-9. Epub 2007 Sep 10.

PMID:
17828301
24.

Role of the unique N-terminal domain of CtBP2 in determining the subcellular localisation of CtBP family proteins.

Bergman LM, Morris L, Darley M, Mirnezami AH, Gunatilake SC, Blaydes JP.

BMC Cell Biol. 2006 Sep 25;7:35.

25.

Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines.

Babbage G, Ottensmeier CH, Blaydes J, Stevenson FK, Sahota SS.

Cancer Res. 2006 Apr 15;66(8):3996-4000.

26.

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.

Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM.

BMC Cancer. 2006 Mar 24;6:80.

27.

C-terminal binding proteins: emerging roles in cell survival and tumorigenesis.

Bergman LM, Blaydes JP.

Apoptosis. 2006 Jun;11(6):879-88. Review.

PMID:
16547590
28.

GC-selective DNA-binding antibiotic, mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis.

Phillips A, Darley M, Blaydes JP.

Oncogene. 2006 Jul 13;25(30):4183-93. Epub 2006 Feb 27.

PMID:
16501602
29.

The mechanisms of regulation of Hdm2 protein level by serum growth factors.

Phillips A, Jones CJ, Blaydes JP.

FEBS Lett. 2006 Jan 9;580(1):300-4. Epub 2005 Dec 19.

30.

MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.

Phelps M, Phillips A, Darley M, Blaydes JP.

J Biol Chem. 2005 Apr 29;280(17):16651-8. Epub 2005 Feb 21.

31.

Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription.

Mirnezami AH, Campbell SJ, Darley M, Primrose JN, Johnson PW, Blaydes JP.

Curr Biol. 2003 Jul 15;13(14):1234-9.

33.

Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription.

Blaydes JP, Luciani MG, Pospisilova S, Ball HM, Vojtesek B, Hupp TR.

J Biol Chem. 2001 Feb 16;276(7):4699-708. Epub 2000 Nov 14.

34.

Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways.

Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, Hupp TR.

Oncogene. 2000 Aug 10;19(34):3829-39.

35.

The development and use of phospho-specific antibodies to study protein phosphorylation.

Blaydes JP, Vojtesek B, Bloomberg GB, Hupp TR.

Methods Mol Biol. 2000;99:177-89. Review. No abstract available.

PMID:
10909085
36.

Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage.

Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, Wynford-Thomas D.

Mol Cell Biol. 2000 Apr;20(8):2803-8.

37.

Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation.

Craig AL, Blaydes JP, Burch LR, Thompson AM, Hupp TR.

Oncogene. 1999 Nov 4;18(46):6305-12.

38.

Activation of p53 protein function in response to cellular irradiation.

Blaydes JP, Sparks A, Hupp TR.

Methods Mol Biol. 1999;113:591-8. No abstract available.

PMID:
10443454
39.
40.
41.

The influence of cell context on the selection pressure for p53 mutation in human cancer.

Wynford-Thomas D, Blaydes J.

Carcinogenesis. 1998 Jan;19(1):29-36. Review.

PMID:
9472689
42.

Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2.

Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D.

Oncogene. 1997 Apr 17;14(15):1859-68.

43.

Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence.

Bond J, Haughton M, Blaydes J, Gire V, Wynford-Thomas D, Wyllie F.

Oncogene. 1996 Nov 21;13(10):2097-104.

PMID:
8950976
45.

Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1.

Bond JA, Blaydes JP, Rowson J, Haughton MF, Smith JR, Wynford-Thomas D, Wyllie FS.

Cancer Res. 1995 Jun 1;55(11):2404-9.

46.

Interaction between p53 and TGF beta 1 in control of epithelial cell proliferation.

Blaydes JP, Schlumberger M, Wynford-Thomas D, Wyllie FS.

Oncogene. 1995 Jan 19;10(2):307-17.

PMID:
7838530
47.

Evasion of p53-mediated growth control occurs by three alternative mechanisms in transformed thyroid epithelial cells.

Wyllie FS, Haughton MF, Blaydes JP, Schlumberger M, Wynford-Thomas D.

Oncogene. 1995 Jan 5;10(1):49-59.

PMID:
7529918
48.

Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification.

Blaydes JE Jr, Kelley EP, Walt JG, DeGryse RE, Harper DG, Novack GD.

J Cataract Refract Surg. 1993 Jul;19(4):481-7.

PMID:
8355154
49.

Initial experience with the HydroSonics instrument to soften cataracts before phacoemulsification.

Brint SF, Blaydes JE, Bloomberg L, Crozafon P, Fine IH, Kraff MC, Filippelli J, Hoffman J.

J Cataract Refract Surg. 1992 Mar;18(2):130-5.

PMID:
1564649
50.

Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression.

Burns JS, Blaydes JP, Wright PA, Lemoine L, Bond JA, Williams ED, Wynford-Thomas D.

Mol Carcinog. 1992;6(2):129-39.

PMID:
1388684

Supplemental Content

Loading ...
Support Center